Skip to content

Study · Measured the body's own peptide · 2025

4 results

The association between 1st trimester serum kisspeptin level and antenatal complications.

Günday ÖK, Vurmaz A, Yılmazer M

Ceska gynekologie1 Jan 2025

PMID40663448 (opens in a new tab)DOI10.48095/cccg2025212 (opens in a new tab)PepBankPUB-40663448
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In pregnant women, first-trimester serum KP-10 was significantly higher in those who later developed fetal growth retardation than in matched controls.

    In plain wordsIn pregnant women, higher natural kisspeptin‑10 levels in early pregnancy were linked to later fetal growth problems.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseFirst-trimester serum KP-10 in fetal growth retardation
    Study

    n: not reported in source

    Comparator
    Matched women with uncomplicated pregnancies
    Outcome group
    Endogenous peptide levels · Reproductive and sexual health

    Source sentences

    Summary
    Among all adverse pregnancy outcomes, the KP-10 level was significantly higher in patients who developed FGR (P = 0.025).
    1 context sentence
    Summary · context
    A prospective case-control study of prospectively collected data. Blood samples of all patients (N = 124) were preserved at -70 °C for the assessment of serum KP-10 and KP-54 levels.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In pregnant women who developed pregnancy-induced hypertension, serum KP-10 showed a trend toward higher levels that was not statistically significant.

    In plain wordsIn pregnant women with high blood pressure in pregnancy, natural kisspeptin‑10 levels trended higher, but the difference was not statistically significant.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeFirst-trimester serum KP-10 in pregnancy-induced hypertension
    Study

    n: not reported in source

    Comparator
    Matched women with uncomplicated pregnancies
    Outcome group
    Endogenous peptide levels · Reproductive and sexual health

    Source sentences

    Summary
    In the patient cohort affected by PIH, either accompanied by preeclampsia or standalone, there was a trend towards higher KP-10 levels (P = 0.059), although statistical significance was not achieved.
    1 context sentence
    Summary · context
    A prospective case-control study of prospectively collected data. Blood samples of all patients (N = 124) were preserved at -70 °C for the assessment of serum KP-10 and KP-54 levels.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    First-trimester serum KP-10 predicted fetal growth retardation with a statistically significant area under the curve of 0.684.

    In plain wordsNatural kisspeptin‑10 levels in early pregnancy predicted later fetal growth problems with modest accuracy.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableKP-10 predicting fetal growth retardation (AUC)
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Reproductive and sexual health

    Measurements

    AUC
    0.684
    KP-10 predicting FGR

    Source sentences

    Summary
    However, regarding KP-10, the calculated cut-off value and the area under the curve (AUC) for predicting the onset of FGR were statistically significant (AUC: 0.684; P = 0.006).
    1 context sentence
    Summary · context
    A prospective case-control study of prospectively collected data. Blood samples of all patients (N = 124) were preserved at -70 °C for the assessment of serum KP-10 and KP-54 levels.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    A model of KP-10, pregnancy-induced hypertension and PAPP-A significantly predicted fetal growth retardation, with an NPV of 98% and a PPV of 21.4%.

    In plain wordsA model that combined natural kisspeptin‑10, high blood pressure in pregnancy and PAPP-A predicted fetal growth problems, mostly by ruling them out.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableKP-10, PIH and PAPP-A model predicting fetal growth retardation
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Reproductive and sexual health

    Measurements

    NPV
    98%
    KP-10, PIH and PAPP-A model
    PPV
    21.4%
    KP-10, PIH and PAPP-A model
    OR
    0.1
    KP-10, PIH and PAPP-A model

    Source sentences

    Summary
    The model established with KP-10, PIH, and pregnancy associated plasma protein-A (PAPP-A) was found to be significant in predicting the development of FGR (P = 0.006; NPV: 98%; PPV: 21.4%; OR: 0.10; 95% CI 0.016-0.611).
    1 context sentence
    Summary · context
    A prospective case-control study of prospectively collected data. Blood samples of all patients (N = 124) were preserved at -70 °C for the assessment of serum KP-10 and KP-54 levels.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 09:43 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.